臨床微生物学のアーカイブ

  • ISSN: 1989-8436
  • ジャーナル h-index: 22
  • 雑誌引用スコア: 7.55
  • ジャーナルのインパクトファクター: 6.38
インデックス付き
  • Jゲートを開く
  • Genamics JournalSeek
  • グローバル インパクト ファクター (GIF)
  • オープンアーカイブイニシアチブ
  • 中国国家知識基盤 (CNKI)
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • OCLC-WorldCat
  • プロクエスト召喚
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ジュネーブ医学教育研究財団
  • Google スカラー
  • シマゴジャーナルランキング
  • 秘密検索エンジン研究所
  • リサーチゲート
このページをシェアする

抽象的な

Mycoplasma Infections and Their Resistance Phenotypes in a Southwestern Area of China

Kailu Wei, GuangRong Guo and Ning Xiao*

The aim was to determine the prevalence and antibiotics resistance of Uroaplasma urealyticum (U.urealyticum) and Mycoplasma hominis (M. hominis) isolated in a southwestern area of china. A total of 1093 patients with Chronic Prostatitis/ Chronic Pelvic Pain Syndrome (CP/CPPS) were included and Expressed Prostatic Secretion (EPS) were collected from the subjects. Antibiotic resistance tests were conducted by using the mycoplasma kits. Of the individuals studied, 17.29% (189/1093) and 3.66% (40/1093) samples were respectively identified to be positive for U.urealyticum and M. hominis in EPS. U.urealyticum were less than 10% (0- 8.99%) resistance to doxycycline, minocycline, azithromycin and josamycin, while they were higher than 60% (60.85%-73.54%) resistance to ciprofloxacin, ofloxacin and gatifloxacin, and the resistance incidence of erythromycin to U.urealyticum was 39.15%). The resistance rate of M. hominis was less than 10% (0-2.5%) to doxycycline, minocycline and josamycin, while they were higher than 60% (62.50%- 87.50%) to azithromycin, erythromycin, ciprofloxacin and ofloxacin, and that of gatifloxiacin was 32.50%. In conclusion, testing for both U.urealyticum and M. hominis in EPS of patients with CP/CPPS should been encouraged and doxycycline, minocycline and josamycin were recommended to treat infections of these strains in patients with CP/CPPS in a southwestern area of china. Further investigations should be focus on the new promising antibiotics against M. genitalium due to increasing resistance of antimicrobial.